Researched by Belong.Life and published by ASCO
Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes.
Belong.Life is a global healthtech provider of high-engagement patient communities and care platforms, supporting millions of patients worldwide.
Among Belong.Life’s brands are the world’s largest social and professional networks for cancer patients (Belong – Beating Cancer Together) and multiple sclerosis patients (BelongMS). With the launch of Dave, Belong.Life has introduced the world’s first real-time conversational AI oncology mentor for cancer patients.
All of Belong’s products and services are multilingual, HIPAA, GDPR and ISO compliant.
